BACKGROUND: Aortic valve calcification increases leaflet stiffness and contributes to the development of calcific aortic valve disease. The molecular and cellular mechanisms underlying calcification ...

The upregulation of PCSK9 expression in endothelial cells of diabetic patients induces ubiquitination of VEGFR2 and inhibits the VEGFR2/ AKT/eNOS -ERK signaling pathway by promoting the interaction of ...

The PCSK9 inhibitor evolocumab (Repatha) got the FDA's blessing for cardiovascular protection, with or without a history of cardiovascular disease (CVD). Evolocumab is now indicated for the wider pool ...

Please provide your email address to receive an email when new articles are posted on . Topline results from two phase 3 trials of a novel oral PCSK9 inhibitor for treatment of HeFH and hyperlipidemia ...

Enlicitide decanoate, an oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer-term data ...

Over the past several days, two major developments have emerged in the world of cholesterol-lowering therapies—specifically concerning the heavy-hitters known as PCSK9 inhibitors. In this letter, I’d ...

LYON, France — Lerodalcibep, a novel, third-generation anti–proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, helps high-risk patients already receiving maximally tolerated statins to ...

Immune checkpoint therapy, particularly anti-PD-1/PD-L1 immunotherapy, have achieved significant results in the treatment of various tumors. However, most cancer patients show a low response rate to ...

The FDA approved lerodalcibep (Lerochol) injections for the treatment of elevated LDL cholesterol in adults, maker LIB Therapeutics announced. A third-generation PCSK9 inhibitor, lerodalcibep is ...

New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of standard of care WILMINGTON, Del.--(BUSINESS WIRE ...

Please provide your email address to receive an email when new articles are posted on . An oral PCSK9 inhibitor lowered LDL cholesterol by up to 60% and improved other lipid parameters at 24 weeks.